2.5 mg/ml Semaglutide: Clearing Up the Concentration Confusion

The misconception: treating concentration as your dose

The most common misreading is this: someone sees "2.5 mg/ml" on a semaglutide product and assumes that is either the dose they should take or a dose that exists within the Wegovy schedule. It isn't either of those things. The mg/ml figure is a concentration, how much semaglutide is dissolved in each millilitre of the pen's solution. It tells you about the medicine's strength per unit of liquid, not about the weekly amount your body receives.

This matters because Wegovy's pre-filled pens are designed to deliver a precise fixed dose when you press the injector. You do not measure volume; the pen does the measuring for you. Knowing the concentration is relevant to pharmacists and clinicians checking for consistency across batches, but for the person using the pen at home, the figure printed on the cap is the dose (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg or 2.4 mg) and that is the one to focus on.

The licensed Wegovy dose schedule is what a prescriber follows when titrating treatment; the underlying concentration of the solution is a manufacturing specification, not an instruction.

Where 2.5 mg/ml actually appears in UK weight-loss medicine

There is a second, entirely separate reason this figure keeps appearing in searches. Mounjaro (tirzepatide) (a dual GIP and GLP-1 receptor agonist made by Eli Lilly) starts treatment at a 2.5 mg dose. That starting dose is often written as "2.5 mg" and sometimes mistakenly rendered with a "/ml" suffix in online discussions, blurring the boundary between the two medicines. Tirzepatide and semaglutide are not the same thing: they work through different pathways, come from different manufacturers, and follow different dose schedules.

If you have been reading about semaglutide dosing and kept landing on results that mention 2.5 mg, it is worth stepping back and checking whether those results are about semaglutide at all, or whether they have slipped into tirzepatide territory; our page on 2.5 mg of semaglutide explains why that figure causes so much confusion and what it actually refers to. The NHS medicines page for semaglutide is a reliable starting point for confirming what the licensed product actually contains.

For a direct comparison of how the two medicines differ in structure and evidence, the Wegovy overview on our site covers both, side by side.

Semaglutide's actual concentration and what it means for storage

Wegovy pens are a 1.34 mg/ml solution, not 2.5 mg/ml. Each pen is pre-set to deliver the prescribed dose in a fixed injection volume, so the concentration stays constant across strengths while the injected volume changes. This is worth knowing if you have ever looked at a pen and thought the numbers didn't match what you expected.

Storage works the same regardless of which strength pen you are on. Keep it in the fridge (the bottom shelf away from the ice compartment is a practical spot, since freezing damages the medicine) and follow the room-temperature window stated in your Patient Information Leaflet if you are travelling or taking it to work. The leaflet, not a general article, is the authority on exactly how long a pen can safely sit outside refrigeration.

If you want to understand how the 2.4 mg maintenance dose relates to weight-loss outcomes in trials, the evidence on semaglutide 2.4 mg and weight-loss percentage covers the STEP 1 data in detail. And for context on how UK private treatment is priced, the Wegovy price comparison sets out what legitimate providers typically include.

When to speak to a prescriber rather than look for more numbers

Concentration figures, dose schedules and titration timing are clinical details that exist to help prescribers manage your treatment safely, not to guide self-adjustment. If you are on Wegovy and uncertain whether your pen contains the right concentration, or if the numbers printed on the device do not match what you expected, the right step is to contact your prescribing service before using it, not to cross-reference online.

The same applies to questions about whether semaglutide is right for you in the first place. Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition, but the medicine is prescription-only because eligibility involves more than a BMI calculation, a prescriber reviews your full medical picture. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

Our FAQs address some of the most common questions about starting treatment, and our clinical team reviews every consultation personally. If you are weighing up whether semaglutide or tirzepatide might be appropriate for your situation, that is exactly the kind of question the weight-loss treatment overview is designed to help you think through before you consult.